Drug Trial Radar · NCT06956690
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
Last checked: Nov 19, 2026Latest source record: Mar 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
180
Planned (sponsor's estimate)
Start
Dec 17, 2025
Primary completion
Jul 2027
Study completion Jul 2027
Sponsor
- Lead sponsor
- Hummingbird BioscienceIndustry
- Sponsor type
- Industry
- First posted
- May 4, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a Phase 1/2, first-in-human, open-label, clinical trial to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of HMBD-501 in patients with advanced-stage, relapsed and/or refractory human epidermal growth factor receptor 3 (HER3)-expressing solid tumors. The study consists of 2 phases: a dose escalation phase (Phase 1) and a dose expansion phase (Phase 2). The primary objectives of Phase 1 are to characterize the overall safety and tolerability profile of increasing doses of HMBD-501 in patients with advanced-stage solid tumors and identify the recommended Phase 2 dose (RP2D) of ENV-501. During Phase 1, successive cohorts of patients will receive escalating doses of HMBD-501. The results of the dose escalation will determine the RP2D and dosing schedule of HMBD-501 to be administered in the Phase 2 part of the study. The primary objective of Phase 2 is to evaluate the preliminary clinical efficacy of HMBD-501 in dose expansion cohorts.
Conditions
- Melanoma (Skin)
- Non Small Cell Lung Cancer
- Breast Cancer
Interventions
ENV-501Biological
ENV-501 is a HER3-targeted antibody-drug conjugate (ADC) with a humanized monoclonal antibody (mAb) conjugated with a chemotherapeutic payload via a linker.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1 (Dose Escalation): Frequency of treatment-emergent adverse eventsTime frame: through study completion, an average of 6 months
- Phase 2 (Dose Expansion): Objective Response Rate (ORR)Time frame: through study completion, an average of 6 months
Locations
7 sites in 2 countries. Site status is shown where the registry gives one.
Research Site
La Jolla, California · Recruiting
Research Site
Indianapolis, Indiana · Recruiting
Research Site
Farmington Hills, Michigan · Recruiting
Research Site
Dallas, Texas · Recruiting
Research Site
San Antonio, Texas · Recruiting
Research Site
Campbelltown, New South Wales, Australia · Withdrawn
Research Site
Miranda, New South Wales, Australia · Withdrawn
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.